Federal Register: May 10, 2002 (Volume 67, Number 91)
DOCID: FR Doc 02-11678
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
NOTICE: NOTICES
ACTION: Meetings:
SUBJECT CATEGORY:
National Cancer Institute; Notice of Closed Meeting
DOCUMENT SUMMARY:
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel. Early Clinical Trials on New AntiCancer Agents with Phase I Emphasis.
Date: June 2526, 2002.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: 6001 Executive Blvd. Bethesda, MD 20892.
Contact Person: Timothy C. Meeker, MD, Scientific Review
Administrator, Special Referral and Resources Branch, Division of
Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8088, Rockville, MD 20852, 301/5941279.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)
Dated: May 2, 2002.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 0211678 Filed 5902; 8:45 am]
BILLING CODE 414001M
SUMMARY:
National Cancer Institute,
DOCUMENT BODY 2:
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel. Early Clinical Trials on New AntiCancer Agents with Phase I Emphasis.
Date: June 2526, 2002.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: 6001 Executive Blvd. Bethesda, MD 20892.
Contact Person: Timothy C. Meeker, MD, Scientific Review
Administrator, Special Referral and Resources Branch, Division of
Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8088, Rockville, MD 20852, 301/5941279.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)
Dated: May 2, 2002.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 0211678 Filed 5902; 8:45 am]
BILLING CODE 414001M